AHMEDABAD:
Homegrown pharma main, Zydus Lifesciences Restricted on Tuesday introduced it has acquired UK-based LiqMeds Group of firms. The acquisition has been made via Zydus’ wholly-owned subsidiary, Zydus Prescribed drugs UK Restricted.
LiqMeds has capabilities and specialisation in growth, manufacturing and provide of oral liquid merchandise for international markets, which it at the moment commercialises via its companions.
The group’s subsidiary LM Manufacturing Restricted (LMML), has an oral liquids manufacturing website at Weedon, Northampton, UK, which provides merchandise to the US and UK markets.
Zydus pays an upfront consideration of GBP 68 million and yearly earn-outs till 2026 relying on achievement of sure agreed milestones in direction of acquisition of the LiqMeds Group of firms.
The transaction might be EPS accretive for Zydus from the primary 12 months of acquisition.
Dr Sharvil Patel, managing director, Zydus Lifesciences Restricted, mentioned, “We consider that liquid orals is a big, rising market and serves unmet wants with important new market growth alternatives. In keeping with our patient-centric method, we consider that oral liquid formulations would assist geriatric and paediatric sufferers, bringing in better ease of comfort and remedy compliance.”
